Serological findings

The Inflammatory Myopathies

Volumn , Issue , 2009, Pages 165-189

  Targoff, Ira N ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

Anti Jo 1; Anti Mi 2; Anti p155 140; Anti PM Scl; Autoantibodies; Dermatomyositis; Immunoprecipitation; Myositis diagnosis; Polymyositis

Indexed keywords

EID: 84892337290     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-60327-827-0_10     Document Type: Chapter

References (111)

1. Reichlin M, Arnett FC. Multiplicity of antibodies in myositis sera. Arthritis Rheum 1984;27:1150-6.
2. Brouwer R, Hengstman GJ, Vree Egberts W, et al. Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 2001;60(2):116-23.
3. Koenig M, Fritzler MJ, Targoff IN, Troyanov Y, Senecal JL. Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther 2007;9(4):R78.
4. Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 1991;70:360-74.
5. Arnett FC, Targoff IN, Mimori T, Goldstein R, Warner NB, Reveille JD. Interrelationship of major histocompatibility complex class II alleles and autoantibodies in four ethnic groups with various forms of myositis. Arthritis Rheum 1996;39:1507-18.
6. Rutjes SA, Vree Egberts WT, Jongen P, Van Den Hoogen F, Pruijn GJ, van Venrooij WJ. Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy. Clin Exp Immunol 1997;109:32-40.
7. Hirakata M, Suwa A, Takada T, et al. Clinical and immunogenetic features of patients with autoantibodies to asparaginyl-transfer RNA synthetase. Arthritis Rheum 2007;56(4):1295-303.
8. Sato S, Kuwana M, Hirakata M. Clinical characteristics of Japanese patients with anti-OJ (anti-isoleucyl-tRNA synthetase) autoantibodies. Rheumatology 2007;46(5):842-5.
9. Oddis CV, Okano Y, Rudert WA, Trucco M, Duquesnoy RJ, Medsger TA Jr. Serum autoantibody to the nucleolar antigen PM-Scl: clinical and immunogenetic associations. Arthritis Rheum 1992;35:1211-7.
10. Gelpi C, Kanterewicz E, Gratacos J, Targoff IN, Rodriguez-Sanchez JL. Coexistence of two antisynthetases in a patient with the antisynthetase syndrome. Arthritis Rheum 1996;39:692-7.
11. Chinoy H, Salway F, Fertig N, et al. In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. Arthritis Res Ther 2006;8(1):R13.
12. Troyanov Y, Targoff IN, Tremblay JL, Goulet JR, Raymond Y, Senecal JL. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine 2005;84(4):231-49.
13. Hengstman GJ, van Engelen BG, Badrising UA, van den Hoogen FH, van Venrooij WJ. Presence of the anti-Jo-1 autoantibody excludes inclusion body myositis. Ann Neurol 1998;44:423.
14. Koffman BM, Rugiero M, Dalakas MC. Immune-mediated conditions and antibodies associated with sporadic inclusion body myositis. Muscle Nerve 1998;21:115-7.
15. Hengstman GJ, ter Laak HJ, van Engelen BG, van Venrooij BG. Anti-Jo-1 positive inclusion body myositis with a marked and sustained clinical improvement after oral prednisone. J Neurol Neurosurg Psychiatry 2001;70(5):706.
16. Chinoy H, Fertig N, Oddis CV, Ollier WE, Cooper RG. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 2007;66(10):1345-9.
17. Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 2006;54(11):3682-9.
18. Oddis CV, Fertig N, Goel A, et al. Clinical and serological characterization of the anti-MJ antibody in childhood myositis [Abstract]. Arthritis Rheum 1997;40:S139.
19. Betteridge Z, Gunawardena H, North J, Slinn J, McHugh N. Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis. Arthritis Rheum 2007;56(9):3132-7.
20. Sato S, Hirakata M, Kuwana M, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 2005;52(5):1571-6.
21. Gunawardena H, Wedderburn LR, North J, et al. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology 2008;47(3):324-8.
22. Gunawardena H, Wedderburn LR, Chinoy H, et al. Novel autoantibodies targeting a p140 protein are a major autoantigen system in juvenile dermatomyositis and a marker of calcinosis [Abstract]. Arthritis Rheum 2008;58:S923.
23. Kaji K, Fujimoto M, Hasegawa M, et al. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology 2007;46(1):25-8.
24. Mierau R, Dick T, Bartz-Bazzanella P, Keller E, Albert ED, Genth E. Strong association of dermatomyositis-specific Mi-2 autoantibodies with a tryptophan at position 9 of the HLA-DR beta chain. Arthritis Rheum 1996;39:868-76.
25. Targoff IN, Trieu EP, Plotz PH, Miller FW. Antibodies to glycyl-transfer RNA synthetase in patients with myositis and interstitial lung disease. Arthritis Rheum 1992;35:821-30.
26. Schmidt WA, Wetzel W, Friedlander R, et al. Clinical and serological aspects of patients with anti-Jo-1 antibodies - an evolving spectrum of disease manifestations. Clin Rheumatol 2000;19(5):371-7.
27. Miller FW, Twitty SA, Biswas T, Plotz PH. Origin and regulation of a disease-specific autoantibody response: antigenic epitopes, spectrotype stability, and isotype restriction of anti-Jo-1 antibodies. J Clin Invest 1990;85:468-75.
28. Stone KB, Oddis CV, Fertig N, et al. Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum 2007;56(9):3125-31.
29. Nishikai M, Reichlin M. Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis: characterization of the Jo-l antibody system. Arthritis Rheum 1980;23:881-8.
30. Targoff IN, Reichlin M. The association between Mi-2 antibodies and dermatomyositis. Arthritis Rheum 1985;28:796-803.
31. Reichlin M, Maddison PJ, Targoff IN, et al. Antibodies to a nuclear/nucleolar antigen in patients with polymyositis-overlap syndrome. J Clin Immunol 1984;4:40-4.
32. Targoff IN. Autoantibodies to aminoacyl-transfer RNA synthetases for isoleucine and glycine: two additional synthetases are antigenic in myositis. J Immunol 1990;144:1737-43.
33. Reeves WH, Nigam SK, Blobel G. Human autoantibodies reactive with the signal-recognition particle. Proc Natl Acad Sci U S A 1986;83:9507-11.
34. Tan EM, Smolen JS, McDougal JS, et al. A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. I. Precision, sensitivity, and specificity [see comments]. Arthritis Rheum 1999;42(3):455-64.
35. Hengstman GJ, van Brenk L, Vree Egberts WT, et al. High specificity of myositis specific autoantibodies for myositis compared with other neuromuscular disorders. J Neurol 2005;252(5):534-7.
36. Hengstman GJ, Vree Egberts WT, Seelig HP, et al. Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 b antigen. Ann Rheum Dis 2006;65:242-5.
37. Mahler M, Raijmakers R, Dahnrich C, Bluthner M, Fritzler MJ. Clinical evaluation of autoantibodies to a novel PM/Scl peptide antigen. Arthritis Res Ther 2005;7(3):R704-13.
38. Kao AH, Lacomis D, Lucas M, Fertig N, Oddis CV. Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum 2004;50(1):209-15.
39. Targoff IN, Johnson AE, Miller FW. Antibody to signal recognition particle in polymyositis. Arthritis Rheum 1990;33:1361-70.
40. Williams J, Lucas M, Fertig N, Medsger TA. Anti-Ku antibody in patients with systemic sclerosis: comparison of clinical features associated with anti-U1RNP, anti-U3RNP, and anti-PM-Scl antibodies [Abstract]. Arthritis Rheum 2005;52:S590-1.
41. Mathews MB, Bernstein RM. Myositis autoantibody inhibits histidyl-tRNA synthetase: a model for autoimmunity. Nature 1983;304:177-9.
42. Vazquez-Abad D, Rothfield NF. Sensitivity and specificity of anti-Jo-1 antibodies in autoimmune diseases with myositis. Arthritis Rheum 1996;39:292-6.
43. Shamim EA, Rider LG, Pandey JP, et al. Differences in idiopathic inflammatory myopathy phenotypes and genotypes between Mesoamerican mestizos and North American Caucasians: ethnogeographic influences in the genetics and clinical expression of myositis. Arthritis Rheum 2002;46(7):1885-93.
44. Mathews MB, Reichlin M, Hughes GRV, Bernstein RM. Anti-threonyl-tRNA synthetase, a second myositis-related autoantibody. J Exp Med 1984;160:420-34.
45. Bunn CC, Bernstein RM, Mathews MB. Autoantibodies against alanyl-tRNA synthetase and tRNAala coexist and are associated with myositis. J Exp Med 1986;163:1281-91.
46. Hirakata M, Suwa A, Nagai S, et al. Anti-KS: identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease. J Immunol 1999;162(4):2315-20.
47. Betteridge Z, Gunawardena H, North J, Slinn J, McHugh N. Anti-synthetase syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia. Rheumatology 2007;46(6):1005-8.
48. Targoff IN, Trieu EP, Miller FW. Reaction of anti-OJ autoantibodies with components of the multi-enzyme complex of aminoacyl-tRNA synthetases in addition to isoleucyl-tRNA synthetase. J Clin Invest 1993;91:2556-64.
49. Targoff IN, Arnett FC. Clinical manifestations in patients with antibody to PL-12 antigen (alanyl-tRNA synthetase). Am J Med 1990;88:241-51.
50. Brouwer R, Vree Egberts W, Jongen PH, van Engelen BG, van Venrooij WJ. Frequent occurrence of anti-tRNA (His) autoantibodies that recognize a conformational epitope in sera of patients with myositis. Arthritis Rheum 1998;41:1428-37.
51. Fathi M, Vikgren J, Boijsen M, et al. Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology. Arthritis Care Res 2008;59(5):677-85.
52. Furuya T, Hakoda M, Tsuchiya N, et al. Immunogenetic features in 120 Japanese patients with idiopathic inflammatory myopathy. J Rheumatol 2004;31(9):1768-74.
53. Yamasaki Y, Yamada H, Nozaki T, et al. Unusually high frequency of autoantibodies to PL-7 associated with milder muscle disease in Japanese patients with polymyositis/dermatomyositis. Arthritis Rheum 2006;54(6):2004-9.
54. Rider LG, Miller FW, Targoff IN, et al. A broadened spectrum of juvenile myositis: myositisspecific autoantibodies in children. Arthritis Rheum 1994;37:1534-8.
55. Feldman BM, Reichlin M, Laxer RM, Targoff IN, Stein LD, Silverman ED. Clinical significance of specific autoantibodies in juvenile dermatomyositis. J Rheumatol 1996;23:1794-97.
56. Espada G, Confalone Gregorian M, Ortiz Z, et al. Serum autoantibodies in juvenile idiopathic inflammatory myopathies (IIM) in a cohort of Argentine patients [Abstract]. Arthritis Rheum 1997;40:S140.
57. Legault D, McDermott J, Crous-Tsanaclis AM, Boire G. Cancer-associated myositis in the presence of anti-Jo1 autoantibodies and the antisynthetase syndrome. J Rheumatol 2008;35(1):169-71.
58. Respicio G, Shwaiki W, Abeles M. A 58-year-old man with anti-Jo-1 syndrome and renal cell carcinoma: a case report and discussion. Conn Med 2007;71(3):151-3.
59. Mozaffar T, Pestronk A. Myopathy with anti-Jo-1 antibodies: pathology in perimysium and neighbouring muscle fibres. J Neurol Neurosurg Psychiatry 2000;68:472-8.
60. Friedman AW, Targoff IN, Arnett FC. Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis. Semin Arthritis Rheum 1996;26:459-67.
61. Douglas WW, Tazelaar HD, Hartman TE, et al. Polymyositis-dermatomyositis- associated interstitial lung disease. Am J Respir Crit Care Med 2001;164(7):1182-5.
62. Clawson K, Oddis CV. Adult respiratory distress syndrome in polymyositis patients with the anti-Jo-1 antibody. Arthritis Rheum 1995;38(10):1519-23.
63. Hirakata M, Nagai S. Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheumatol 2000;12(6):501-8.
64. Oddis CV, Medsger TA Jr, Cooperstein LA. A subluxing arthropathy associated with the anti-Jo-1 antibody in polymyositis/dermatomyositis. Arthritis Rheum 1990;33:1640-5.
65. Romisch K, Miller FW, Dobberstein B, High S. Human autoantibodies against the 54 kDa protein of the signal recognition particle block function at multiple stages. Arthritis Res Ther 2006;8(2):R39.
66. Satoh T, Okano T, Matsui T, et al. Novel autoantibodies against 7SL RNA in patients with polymyositis/dermatomyositis. J Rheumatol 2005;32(9):1727-33.
67. Hengstman GJ, ter Laak HJ, Vree Egberts WT, et al. Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis 2006;65(12):1635-8.
68. Miller T, Al Lozi MT, Lopate G, Pestronk A. Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry 2002;73(4):420-8.
69. Joffe MM, Love LA, Leff RL, et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med 1993;94:379-87.
70. Dimitri D, Andre C, Roucoules J, Hosseini H, Humbel RL, Authier FJ. Myopathy associated with anti-signal recognition peptide antibodies: clinical heterogeneity contrasts with stereotyped histopathology. Muscle Nerve 2007;35(3):389-95.
71. Leff RL, Burgess SH, Miller FW, et al. Distinct seasonal patterns in the onset of adult idiopathic inflammatory myopathy in patients with anti-Jo-1 and anti-signal recognition particle autoantibodies. Arthritis Rheum 1991;34:1391-6.
72. Nilasena DS, Trieu EP, Targoff IN. Analysis of the Mi-2 autoantigen of dermatomyositis. Arthritis Rheum 1995;38:123-8.
73. Seelig HP, Renz M, Targoff IN, Ge Q, Frank MB. Two forms of the major antigenic protein of the dermatomyositis-specific Mi-2 autoantigen. Arthritis Rheum 1996;39:1769-71.
74. Ge Q, Nilasena DS, O'Brien CA, Frank MB, Targoff IN. Molecular analysis of a major antigenic region of the 240-kD protein of Mi-2 autoantigen. J Clin Invest 1995;96:1730-7.
75. Seelig HP, Moosbrugger I, Ehrfeld H, Fink T, Renz M, Genth E. The major dermatomyositisspecific Mi-2 autoantigen is a presumed helicase involved in transcriptional activation. Arthritis Rheum 1995;38:1389-99.
76. Zhang Y, Ng HH, Erdjument-Bromage H, Tempst P, Bird A, Reinberg D. Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes Dev 1999;13:1924-35.
77. Zhang Y, LeRoy G, Seelig HP, Lane WS, Reinberg D. The dermatomyositis-specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities. Cell 1998;95:279-89.
78. Wang HB, Zhang Y. Mi2, an auto-antigen for dermatomyositis, is an ATP-dependent nucleosome remodeling factor. Nucleic Acids Res 2001;29(12):2517-21.
79. Wade PA, Gegonne A, Jones PL, Ballestar E, Aubry F, Wolffe AP. Mi-2 complex couples DNA methylation to chromatin remodelling and histone deacetylation. Nat Genet 1999;23:62-6.
80. Hausmanowa-Petrusewicz I, Kowalska-Oledzka E, Miller FW, et al. Clinical, serologic, and immunogenetic features in Polish patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997;40:1257-66.
81. Okada S, Weatherhead E, Targoff IN, Wesley R, Miller FW. International Myositis Collaborative Study Group. Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune muscle disease. Arthritis Rheum 2003;48(8):2285-93.
82. Brouwer R, Vree Egberts WT, Hengstman GJ, et al. Autoantibodies directed to novel components of the PM/Scl complex, the human exosome. Arthritis Res 2002;4(2):134-8.
83. Ge Q, Wu Y, Trieu EP, Targoff IN. Analysis of the specificity of anti-PM-Scl autoantibodies. Arthritis Rheum 1994;37(10):1445-52.
84. Alderuccio F, Chan EKL, Tan EM. Molecular characterization of an autoantigen of PM-Scl in the polymyositis/scleroderma overlap syndrome: a unique and complete human cDNA encoding an apparent 75-kD acidic protein of the nucleolar complex. J Exp Med 1991;173:941-52.
85. Raijmakers R, Renz M, Wiemann C, et al. PM-Scl-75 is the main autoantigen in patients with the polymyositis/scleroderma overlap syndrome. Arthritis Rheum 2004;50(2):565-9.
86. Schilders G, Egberts WV, Raijmakers R, Pruijn GJ. C1D is a major autoantibody target in patients with the polymyositis-scleroderma overlap syndrome. Arthritis Rheum 2007;56(7):2449-54.
87. Schnitz W, Taylor-Albert E, Targoff IN, Reichlin M, Scofield RH. Anti-PM/Scl autoantibodies in patients without clinical polymyositis or scleroderma. J Rheumatol 1996;23:1729-33.
88. Genth E, Mierau R, Genetzky P, et al. Immunogenetic associations of scleroderma-related antinuclear antibodies. Arthritis Rheum 1990;33:657-65.
89. Jablonska S, Blaszczyk M. Scleroderma overlap syndromes. Adv ExpMed Biol 1999;455:85-92.
90. Mimori T, Hinterberger M, Pettersson I, Steitz JA. Autoantibodies to the U2 small nuclear ribonucleoprotein in scleroderma-polymyositis overlap syndrome. J Biol Chem 1984;259:560-5.
91. Okano Y, Medsger TA Jr. Newly identified U4/6 snRNP-binding proteins by serum autoantibodies from a patient with systemic sclerosis. J Immunol 1991;146:535-42.
92. Okano Y, Targoff IN, Oddis CV, et al. Anti-U5 small nuclear ribonucleoprotein (snRNP) antibodies: a rare anti-U snRNP specificity. Clin Immunol Immunopathol 1996;81:41-7.
93. Tormey VJ, Bunn CC, Denton CP, Black CM. Anti-fibrillarin antibodies in systemic sclerosis. Rheumatology 2001;40(10):1157-62.
94. Frank MB, McCubbin VR, Trieu EP, Wu Y, Isenberg DA, Targoff IN. The association of anti-Ro52 autoantibodies with myositis and scleroderma autoantibodies. J Autoimmun 1999;12:137-42.
95. Watkins C, Fertig N, Lucas M, Burlingame RW, Oddis CV. The diagnostic utility of anti-52 kDa Ro/SSA autoantibody testing in patients with idiopathic inflammatory myopathy and other myopathic syndromes [Abstract]. Arthritis Rheum 2004.
96. Casciola-Rosen LA, Pluta AF, Plotz PH, et al. The DNA mismatch repair enzyme PMS1 is a myositis-specific autoantigen. Arthritis Rheum 2001;44(2):389-96.
97. Targoff IN, Trieu EP, Sontheimer RD. Autoantibodies to 155 kd and Se antigens in patients with clinically-amyopathic dermatomyositis [Abstract]. Arthritis Rheum 2000;43:S194.
98. Betteridge ZE, Gunawardena H, Chinoy H, Ollier WER, Cooper RG, McHugh NJ. Clinical and immunogenetic characteristics of patients with autoantibodies to small ubiquitin-like modifier activating enzyme in dermatomyositis [Abstract]. Arthritis Rheum 2008;58:S227-8.
99. Tillie-Leblond I, Wislez M, Valeyre D, et al. Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset. Thorax 2008;63(1):53-9.
100. Katsumata Y, Ridgway WM, Oriss T, et al. Species-specific immune responses generated by histidyl-tRNA synthetase immunization are associated with muscle and lung inflammation. J Autoimmunity 2007;29(2-3):174-86.
101. Casciola-Rosen L, Andrade F, Ulanet D, Wong WB, Rosen A. Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity. J Exp Med 1999;190:815-26.
102. Casciola-Rosen L, Nagaraju K, Plotz P, et al. Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 2005;201(4):591-601.
103. Targoff IN. Immune manifestations of inflammatory muscle disease. Rheum Dis Clin North Am 1994;20(4):863.
104. Targoff IN. Laboratory testing in the diagnosis and management of idiopathic inflammatory myopathies. Rheum Dis Clin North Am 2002;28:859-890.
105. Brouwer R, Pruijn GJ, van Venrooij WJ. The human exosome: an autoantigenic complex of exoribonucleases in myositis and scleroderma. Arthritis Research 2001;3(2):102-106.
106. Mahler M, Raijmakers R. Novel aspects of autoantibodies to the PM/Scl complex: clinical, genetic and diagnostic insights. Autoimmunity Reviews 2007;6(7):432-437.
107. Craft J, Mimori T, Olsen TL, Hardin JA. The U2 small nuclear ribonucleoprotein particle as an autoantigen. Analysis with sera from patients with overlap syndromes. J Clin Invest 1988;81:1716-1724.
108. Arad-Dann H, Isenberg D, Ovadia E, Shoenfeld Y, Sperling J, Sperling R. Autoantibodies against a nuclear 56-kDa protein: a marker for inflammatory muscle disease. J Autoimmun 1989;2:877-888.
109. Targoff IN, Hanas J. The polymyositis-associated Fer antigen is elongation factor 1a. Arthritis & Rheumatism 32, S81. 1989. (Abstract)
110. Targoff IN, Arnett FC, Berman L, O'Brien CA, Reichlin M. Anti-KJ: a new antibody associated with the myositis/lung syndrome that reacts with a translation-related protein. J Clin Invest 1989;84:162-172.
111. Dagenais A, Bibor-Hardy V, Senecal JL. A novel autoantibody causing a peripheral fluorescent antinuclear antibody pattern is specific for nuclear pore complexes. Arthritis Rheum 1988;31(10):1322-1327.